Business
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that Maria Maccecchini, Ph.D., President and CEO, will present at Fierce Biotech Week 2026 taking place in Boston, May 12-14, 2026. Presentation Details: Title: "The Multi-Protei
About this update from Annovis Bio, Inc.
[{"type":"image","alt":"Annovis Bio Inc.","displaySize":"","headline":null,"caption":"Annovis Bio Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":200,"url":"https://media.zenfs.com/en/globenewswire.com/00e49d5ebf66ac512dbaabeac6cdd6eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/V2aX3COZJf3aT17udXAGAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MA--/https://media.zenfs.com/en/globenewswire.com/00e49d5ebf66ac512dbaabeac6cdd6eb","width":200,"height":200},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/V2aX3COZJf3aT17udXAGAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MA--/https://media.zenfs.com/en/globenewswire.com/00e49d5ebf66ac512dbaabeac6cdd6eb","width":200,"height":200}},"lazy":false},{"type":"text","content":"MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that Maria Maccecchini, Ph.D., President and CEO, will present at Fierce Biotech Week 2026 taking place in Boston, May 12-14, 2026.","length":458,"tagName":"p"},{"type":"text","content":"Presentation Details:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Title: "The Multi-Protein Reality of Alzheimer's Disease: What the Science Has Known for Decades and What the Field Has Yet to Accept"","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"Presenter: Maria Maccecchini, Ph.D., President and CEO","length":54,"tagName":"p"}]},{"val":[{"type":"text","content":"Date: Wednesday, May 13, 2026","length":29,"tagName":"p"}]},{"val":[{"type":"text","content":"Time: 1:40 PM - 2:05 PM","length":23,"tagName":"p"}]},{"val":[{"type":"text","content":"Location: Picasso 4&5","length":25,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":279,"olType":false},{"type":"text","content":"The presentation will trace the scientific foundation for understanding AD as a disease driven by multiple neurotoxic aggregating proteins and examine the historical gap between that evidence and the field's reliance on a single-protein approach. Dr. Maccecchini will make the case supporting the importance of the full spectrum of neurotoxi...